Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Jun 19.

Published in final edited form as: Vaccine. 2008 Apr 30;26(26):3312–3321. doi: 10.1016/j.vaccine.2008.03.100

Table 2.

Pre-challenge Tat–specific cellular immune responses.

		ELISPOT			Proliferation

Macaques	Vaccination group	Peak^a (SFC)	Responders^b (%)	Frequency^c (Mean %)	Peak^a (SI)	Responders^b (%)	Frequency^c (%)
Cynomolgus
	Tat protein	26 (0 -77)	67	7	5.2 (<2 – 15.9)	78	12
	Adeno-Tat	51 (0 – 237)	78	14	4.7 (<2 – 12.4)	67	10
Rhesus
	Tat protein	22 (0 - 93)	38	6	6.8 (<2 – 14.4)	88	34
	Adeno-Tat	109 (0 - 260)	88	22	4.7 (<2 – 13.2)	88	13

^a

Mean (range) of peak positive responses, weeks 2-50.

^b

Percent of macaques exhibiting a positive response, weeks 2-50.

^c

Mean of frequency of positive responses for each macaque over the 8 to 10 time points evaluated.